Intraretinal vessel treatment for central retinal vein occlusion

Intraretinal vessel treatment for central retinal vein occlusion - IVTEC

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007958

Enrollment

Registered

2012-05-15

Start date

2012-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cetntral Retinal Artery and Vein Occlusion

Interventions

cannulation bevacizumab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Participants were eligible for inclusion in the study if the CRVO duration was 6 months or less, the best-corrected visual acuity (BCVA) was between 15-65 ETDRS letters, and the mean central subfoveal thickness was more than 300 micrometers as measured using OCT.

Exclusion criteria

Exclusion criteria: Key exclusion criteria included CRVO with neovascularization, any previous treatment for CRVO, intraocular surgery during the previous 3 months, vascular retinopathy arising from other causes, glaucoma with an advanced visual field defect or uncontrolled ocular hypertension (25 mmHg) despite full therapy, and myocardial infarction or stroke during the last 12 months. All the participants provided their written informed consent.

Design outcomes

Primary

Measure	Time frame
Visual acuity (ETDRS charts), Retinal thickness	—

Countries

Japan

Contacts

Public ContactKazuaki Kadonosono

Yokohama City University Medical Center Department of Ophthalmology

kado@med.yokohama-cu.ac.jp045-261-5656

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026